JP2020193206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020193206A5 JP2020193206A5 JP2020134010A JP2020134010A JP2020193206A5 JP 2020193206 A5 JP2020193206 A5 JP 2020193206A5 JP 2020134010 A JP2020134010 A JP 2020134010A JP 2020134010 A JP2020134010 A JP 2020134010A JP 2020193206 A5 JP2020193206 A5 JP 2020193206A5
- Authority
- JP
- Japan
- Prior art keywords
- cladribine
- administered
- phase
- total dose
- reached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 8
- 229960002436 cladribine Drugs 0.000 claims 8
- 230000001939 inductive effect Effects 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (2)
- 以下の逐次ステップ:
(i)誘導期、ここでは、クラドリビン医薬製剤が投与され、且つ、当該誘導期の終了時点で到達するクラドリビンの総用量が1.7mg/kg〜3.5mg/kgであり;
(ii)無クラドリビン期、ここでは、クラドリビンが全く投与されず;
(iii)維持期、ここでは、クラドリビン医薬製剤が投与され、且つ、当該維持期の終了時点で到達するクラドリビンの総用量が上記誘導期(i)の終了時点で到達するクラドリビンの総用量より少なく;
(iv)無クラドリビン期、ここでは、クラドリビンが全く投与されない、
に従って経口投与される、多発性硬化症の治療用医薬製剤の製造のためのクラドリビンの使用。 - 明細書に記載の発明。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63866904P | 2004-12-22 | 2004-12-22 | |
EP04106909 | 2004-12-22 | ||
EP04106909.7 | 2004-12-22 | ||
US60/638,669 | 2004-12-22 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018129918A Division JP2018165271A (ja) | 2004-12-22 | 2018-07-09 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020193206A JP2020193206A (ja) | 2020-12-03 |
JP2020193206A5 true JP2020193206A5 (ja) | 2021-08-19 |
Family
ID=36227798
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007547486A Active JP5795456B2 (ja) | 2004-12-22 | 2005-12-20 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
JP2013113850A Active JP5908863B2 (ja) | 2004-12-22 | 2013-05-30 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
JP2015120875A Active JP6092945B2 (ja) | 2004-12-22 | 2015-06-16 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
JP2016078293A Active JP6290962B2 (ja) | 2004-12-22 | 2016-04-08 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
JP2017022375A Active JP6430554B2 (ja) | 2004-12-22 | 2017-02-09 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
JP2018129918A Pending JP2018165271A (ja) | 2004-12-22 | 2018-07-09 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
JP2020134010A Pending JP2020193206A (ja) | 2004-12-22 | 2020-08-06 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007547486A Active JP5795456B2 (ja) | 2004-12-22 | 2005-12-20 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
JP2013113850A Active JP5908863B2 (ja) | 2004-12-22 | 2013-05-30 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
JP2015120875A Active JP6092945B2 (ja) | 2004-12-22 | 2015-06-16 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
JP2016078293A Active JP6290962B2 (ja) | 2004-12-22 | 2016-04-08 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
JP2017022375A Active JP6430554B2 (ja) | 2004-12-22 | 2017-02-09 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
JP2018129918A Pending JP2018165271A (ja) | 2004-12-22 | 2018-07-09 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
Country Status (24)
Country | Link |
---|---|
US (2) | US7713947B2 (ja) |
EP (6) | EP1827461B1 (ja) |
JP (7) | JP5795456B2 (ja) |
KR (1) | KR20070091662A (ja) |
AR (1) | AR052830A1 (ja) |
AU (2) | AU2005318190B2 (ja) |
BR (1) | BRPI0517132B8 (ja) |
CA (2) | CA2588966C (ja) |
CY (3) | CY1112614T1 (ja) |
DK (2) | DK3332789T3 (ja) |
EA (1) | EA015799B1 (ja) |
ES (1) | ES2921858T3 (ja) |
FR (1) | FR18C1008I2 (ja) |
HR (1) | HRP20120228T1 (ja) |
HU (2) | HUE059133T2 (ja) |
IL (2) | IL183930A0 (ja) |
LT (2) | LT3332789T (ja) |
LU (1) | LUC00064I2 (ja) |
MX (1) | MX2007007610A (ja) |
NO (1) | NO20073813L (ja) |
PL (3) | PL3332789T3 (ja) |
SG (1) | SG160391A1 (ja) |
SI (2) | SI3332789T1 (ja) |
WO (1) | WO2006067141A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007135172A2 (en) * | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
GB2564717A (en) * | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
CA3083328A1 (en) * | 2017-11-24 | 2019-05-31 | Merck Patent Gmbh | Cladribine regimen for use intreating progressive forms of multiple sclerosis |
GB2601786A (en) * | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
JPH10512549A (ja) | 1994-12-22 | 1998-12-02 | オーソ・フアーマシユーチカル・コーポレーシヨン | 可溶性の2−クロロ−2’−デオキシアデノシン配合物 |
US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
JP4757632B2 (ja) | 2002-09-25 | 2011-08-24 | ブリガム ヤング ユニバーシティー | 2’−デオキシグアノシンから2−クロロ−2’−デオキシアデノシンを調製する方法 |
GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
AU2004216485B2 (en) * | 2003-02-25 | 2009-06-11 | Merck Serono Sa | Combined use of ribavirin and interferon beta in demyelinating diseases |
MXPA05010330A (es) | 2003-03-28 | 2006-05-31 | Ivax Corp | Formulaciones de cladribina para el mejor suministro oral y a traves de la mucosa. |
JP5256611B2 (ja) * | 2003-03-28 | 2013-08-07 | アレス トレーディング ソシエテ アノニム | クラドリビンの経口製剤 |
WO2007135172A2 (en) * | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
-
2005
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es active Active
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en active Active
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja active Active
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 EP EP22166610.0A patent/EP4070800A1/en active Pending
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en active Active
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en active Active
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en active Active
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en active Active
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 CA CA2588966A patent/CA2588966C/en active Active
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Application Discontinuation
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en active Application Filing
- 2005-12-20 CA CA3087419A patent/CA3087419C/en active Active
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en active Active
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-03-13 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja active Active
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja active Active
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja active Active
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja active Active
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending